The effect of different doses of fluvastatin on inflammatory markers in the early phase of acute coronary syndrome

Clinica Chimica Acta

Volumn 368, Issue 1-2, 2006, Pages 183-187

  Yang, Jun ^a   Li, Xiang Ping ^a   Zhao, Shui Ping ^a   Li, Jiang ^a   Li, Jing Dong ^b   Xie, Xiao Ming ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

Acute coronary syndrome; Fluvastatin; High sensitive C reactive protein; Tumor necrosis factor

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; TICLOPIDINE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; TURBIDIMETRY;

ACUTE DISEASE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; INDOLES; INFLAMMATION MEDIATORS; LIPID METABOLISM; MALE; MIDDLE AGED; SYNDROME; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33646829671     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2005.12.029     Document Type: Article

References (36)

1. Libby P. Molecular bases of the acute coronary syndromes. Circulation 91 (1995) 2844-2850
2. Dupuis J., Tardif J.C., Cernacek P., et al. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 99 (1999) 3227-3233
3. Maseri A. Inflammation in acute coronary syndromes. Haematologica 86 11 Suppl 2 (2001) 1-2
4. Ross R. Mechanisms of disease: atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
5. Ridker P.M., Henneckens C.H., Buring J.E., et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 (2000) 836-843
6. Ridker P.M., Rifar N., Pfeffer M., et al. Elevation of tumor necrosis factor-a and increased risk of recurrent coronary events after myocardial infarction. Circulation 101 (2000) 2149-2153
7. Munford R.S. Statins and the acute-phase response. N Engl J Med 344 (2001) 2016-2018
8. Rifai N., and Ridker P.M.A. Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. Clin Chem 47 1 (2001) 28-30
9. Ridker P.M., Cushman M., Stampfer M.J., et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336 (1997) 973-979
10. Ridker P.M., Rifai N., Pfeffer M.A., et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol concentrations. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 98 (1998) 839-844
11. Kuller L.H., Tracy R.P., Shaten J., et al. Relationship of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol 144 (1996) 537-547
12. Koenig W., Sund M., Froelich M., et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (monitoring trends and determinants in cardiovascular disease) Augsberg Cohort Study, 1984 to 1992. Circulation 99 (1999) 237-242
13. Ridker P.M. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103 (2001) 1813-1818
14. Rosenson R.S., and Koenig W. Utility of inflammatory markers in the management of coronary artery disease. Am J Cardiol 92 (2003) 10i-18i [suppl]
15. Morrow D.A., Rifai N., Antman E.M., et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: TIMI 11A substudy. Thrombolysis in myocardial infarction. J Am Coll Cardiol 31 (1998) 1460-1465
16. Cesari M., Penninx B.W., Newman A.B., et al. Inflammatory markers and onset of cardiovascular events: results from health ABC study. Circulation 108 19 (2003) 2317-2322
17. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the scandinavian simvastatin survival study(4s). Lancet 344 (1994) 1383-1389
18. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol concentrations. The long-term intervention with pravastatin in ischaemic disease (LIPLD) study group. N Eng J Med 339 (1998) 1349-1357
19. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvostatin on early recurrent ischemic events in acute coronary syndromes :the MIRACL study: a randomized controlled trial. JAMA 285 13 (2001) 1711-1718
20. Ridker P.M., Rifai N., Clearfieid M., et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344 (2001) 1959-1965
21. Romano M., Mezzetti A., Marulli C., et al. Fluvastatin reduces soluble P-selectin and ICAM-1 concentrations in hypercholesterolemic patients: role of nitric oxide. J Investig Med 48 (2000) 183-189
22. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 109 Suppl I (2004) III39-III43
23. Plenge J.K., Hernandez T.L., Weil K.M., et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 106 (2002) 1447-1452
24. Skoog T., Dichtl W., Boquist S., et al. Plasma tumour necrosis factor-a and early carotid atherosclerosis in healthy middle-aged men. Eur Heart J 23 (2002) 376-383
25. Jovinge S., Hamsten A., Tornvall P., et al. Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease. Metabolism 47 (1998) 113-118
26. Ridker P.M., Rifai N., Rose L., et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol concentrations in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557-1565
27. Correia L.C., Spositi A.C., Lima J.C., et al. Anti-inflammatory effect of atorvastatin (80 mg) in unstable angina pectoris and non-Q-wave acute myocardial infarction. Am J Cardiol 92 (2003) 298-301
28. Li J., Zhao S.P., Peng D.Q., et al. Early effect of pravastatin on serum soluble CD40L, matrix metalloproteinase-9, and C-reactive protein in patients with acute myocardial infarction. Clin Chem 50 9 (2004) 1696-1699
29. Ostadal P., Alan D., Hajek P., et al. The effect of early treatment by cerivastatin on the serum concentration of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction. Mol Cell Biochem 246 1-2 (2003) 45-50
30. Olsson A.G., and Schwartz G.G. Early initiation of treatment with statins in acute coronary syndromes. Ann Med 34 (2002) 37-41
31. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 (2004) 1132-1134
32. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
33. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352 (2005) 29-38
34. Luo Y., Jiang D., Wen D., et al. Change in serum interleukin-6 and high-sensitivity C-reactive protein concentrations in patients with acute coronary syndrome and their responses to simvastatin. Heart Vessels 19 6 (2004) 257-262
35. Macin S.M., Perna E.R., Farias E.F., et al. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study. Am Heart J 149 3 (2005) 451-457
36. Bonetti P.O., Lerman L.O., Napoli C., et al. Statin effects beyond lowering-are they clinically relevant?. Eur Heart J 24 (2003) 225-248